AURKB and head and neck squamous cell carcinoma: Previous studies have indicated that inhibition of AURKB can enhance radiosensitivity in androgen blockade-resistant prostate cancer 29 and suppresses the growth of cetuximab-resistant head and neck squamous cell carcinoma (HNSCC) cells 30.